Therapeutics

Kato Pharmaceuticals will study the efficacy of Resolv ER for the treatment of vitreomacular attachment.

Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.

After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

During the Glaucoma 360 New Horizons Forum, the spotlight was cast upon sustained release injectables, including innovations that have been flourishing over the past year despite, or perhaps because of, a continuing worldwide pandemic.

Jay S. Duker, MD, who presented data at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, noted that previously treated patients showed a significantly reduced treatment

The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.

During a presentation at the Bascom Palmer Eye Institute's Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition conference, David S. Boyer, MD, explained that the drug, which is being considered to treat diabetic retinopathy, renal disease, and age-related macular degeneration, is intended to be an alternative therapy to monthly chronically administered intravitreal injections of anti-VEGF drugs.

Ora Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, speak with Ophthalmology Times®' Sheryl Stevenson to discuss some of the cutting-edge advancements in therapies and diagnostics for the treatment of glaucoma patients.

Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times®' Sheryl Stevenson on what attendees can expect from this year's annual meeting.

According to the company, its C.STIM IPL system is based on intense pulsed light technology for the treatment of dry eye disease.

Presbyopia-correcting drops represent a whole new product category—one with a lot of upsides for clinicians who want to help their patients see well at all distances.

NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.

According to investigators, the implant can provide a sustained infusion of drug to the retina

A team of investigators has conducted ocular pharmacokinetic studies, including metabolism, providing valuable information for ocular drug development.

The future of this age-related condition is bright and in focus.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.

Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.

Numerous studies have shown that adherence declines with more complex regimens of more than 1 or 2 bottles.

According to the company, A197 is a novel, first-in-class, topical immunomodulatory agent which will move into Phase II clinical trials in dry eye patients.

Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.

Kathryn M. Hatch, MD, details how collagen CXL is evolving with the goals of reducing complications and actually improving visual acuity.

Cathleen McCabe, MD, presents results of a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

Physician offers practical advice for the use of systems.

Administration has minimal impact on patients’ perception of pain.